Literature DB >> 24577788

Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma.

Paolo A Ascierto1, Kim Margolin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24577788     DOI： 10.1002/cncr.28622

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  15 in total

1.  The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.

Authors:  Laura J Vella; Miles C Andrews; Anupama Pasam; Katherine Woods; Andreas Behren; Jonathan S Cebon
Journal:  Oncoimmunology       Date:  2014-07-03       Impact factor: 8.110

2.  Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma.

Authors:  F Aya; A Fernandez-Martinez; L Gaba; I Victoria; M Tosca; E Pineda; P Gascon; A Prat; A Arance
Journal:  Clin Transl Oncol       Date:  2016-05-04       Impact factor: 3.405

Review 3.  Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.

Authors:  Francesco Spagnolo; Paola Ghiorzo; Paola Queirolo
Journal:  Oncotarget       Date:  2014-11-15

Review 4.  BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.

Authors:  Francesco Spagnolo; Paola Ghiorzo; Laura Orgiano; Lorenza Pastorino; Virginia Picasso; Elena Tornari; Vincenzo Ottaviano; Paola Queirolo
Journal:  Onco Targets Ther       Date:  2015-01-16       Impact factor: 4.147

Review 5.  First-line treatment of metastatic melanoma: role of nivolumab.

Authors:  Jeremy Force; April Ks Salama
Journal:  Immunotargets Ther       Date:  2017-02-13

6.  Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.

Authors:  Henner Stege; Maximilian Haist; Michael Schultheis; Maria Isabel Fleischer; Peter Mohr; Friedegund Meier; Dirk Schadendorf; Selma Ugurel; Elisabeth Livingstone; Lisa Zimmer; Rudolf Herbst; Claudia Pföhler; Katharina Kähler; Michael Weichenthal; Patrick Terheyden; Dorothée Nashan; Dirk Debus; Martin Kaatz; Fabian Ziller; Sebastian Haferkamp; Andrea Forschner; Ulrike Leiter; Alexander Kreuter; Jens Ulrich; Johannes Kleemann; Fabienne Bradfisch; Stephan Grabbe; Carmen Loquai
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

7.  The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK.

Authors:  James Larkin; Anthony J Hatswell; Paul Nathan; Maximilian Lebmeier; Dawn Lee
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

8.  Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

Authors:  Zachary A Cooper; Alexandre Reuben; Christine N Spencer; Peter A Prieto; Jacob L Austin-Breneman; Hong Jiang; Cara Haymaker; Vancheswaran Gopalakrishnan; Michael T Tetzlaff; Dennie T Frederick; Ryan J Sullivan; Rodabe N Amaria; Sapna P Patel; Patrick Hwu; Scott E Woodman; Isabella C Glitza; Adi Diab; Luis M Vence; Jaime Rodriguez-Canales; Edwin R Parra; Ignacio I Wistuba; Lisa M Coussens; Arlene H Sharpe; Keith T Flaherty; Jeffrey E Gershenwald; Lynda Chin; Michael A Davies; Karen Clise-Dwyer; James P Allison; Padmanee Sharma; Jennifer A Wargo
Journal:  Oncoimmunology       Date:  2016-02-02       Impact factor: 8.110

9.  Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.

Authors:  Maria Gonzalez-Cao; Aram Boada; Cristina Teixidó; María Teresa Fernandez-Figueras; Clara Mayo; Francesc Tresserra; Jean Bustamante; Santiago Viteri; Enrique Puertas; Mariacarmela Santarpia; Aldo Riso; Feliciano Barron; Niki Karachaliou; Rafael Rosell
Journal:  Oncotarget       Date:  2016-08-30

10.  Immunotherapy Outcomes in Advanced Melanoma in Relation to Age.

Authors:  Krishna Joshi; Dinesh Atwal; Rahul Ravilla; Yadav Pandey; Naveen Yarlagadda; Sunil Kakadia; Issam Makhoul; Laura Hutchins; Fade Mahmoud
Journal:  Perm J       Date:  2020-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.